1183251-84-4 Usage
Molecular Structure
The compound consists of a piperazine ring and an ethanol group attached to a phenyl ring with an amino and trifluoromethyl substituent.
Chemical Classification
It is a chemical compound with a complex structure.
Pharmacological Uses
It is commonly used in pharmaceutical research and development due to its potential as a central nervous system depressant and its ability to modulate serotonin receptors.
Potential Applications
It has been studied for its potential use in the treatment of psychiatric disorders and has shown promising results in preclinical studies. Additionally, it has also been investigated for its potential to act as an analgesic and may have applications in pain management.
Further Research
Further research is needed to fully understand its biological activity and potential therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1183251-84-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,3,2,5 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1183251-84:
(9*1)+(8*1)+(7*8)+(6*3)+(5*2)+(4*5)+(3*1)+(2*8)+(1*4)=144
144 % 10 = 4
So 1183251-84-4 is a valid CAS Registry Number.
1183251-84-4Relevant articles and documents
Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors
Wang, Hai,Wang, Xiaowei,Wang, Zhenwei,Yu, Zhuangzhuang,Zhang, Yan,Zhao, Liwen
, (2022/02/16)
The transforming growth factor type β receptor I (TGF-β R1, also known as activin-like kinase 5 or ALK5) plays a significant role in the pathogenesis of multiple diseases such as malignant tumors and tissue fibrosis. Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. Herein, a novel series of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives was synthesized and identified as ALK5 inhibitors. Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. Compound 8h also showed favorable pharmacokinetic profile and ameliorated hERG inhibition. More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity.
